Malegra DXT Plus: Dual-Action Therapy for Erectile Dysfunction and Premature Ejaculation
| Product dosage: 130mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.77 | $53.22 (0%) | 🛒 Add to cart |
| 60 | $1.42 | $106.44 $85.35 (20%) | 🛒 Add to cart |
| 90 | $1.31 | $159.66 $117.48 (26%) | 🛒 Add to cart |
| 120 | $1.25 | $212.87 $149.61 (30%) | 🛒 Add to cart |
| 180 | $1.19 | $319.31 $214.88 (33%) | 🛒 Add to cart |
| 270 | $1.15
Best per pill | $478.97 $311.28 (35%) | 🛒 Add to cart |
Similar products
Malegra DXT Plus is a clinically-formulated combination medication designed to address two of the most prevalent male sexual health concerns simultaneously: erectile dysfunction (ED) and premature ejaculation (PE). This advanced pharmaceutical solution integrates the proven efficacy of Sildenafil Citrate, a potent PDE5 inhibitor, with Dapoxetine, a selective serotonin reuptake inhibitor (SSRI) specifically developed for PE. It offers a comprehensive therapeutic approach, enabling men to achieve and sustain firmer erections while significantly prolonging intravaginal ejaculatory latency time. By targeting both physiological and psychological components of sexual performance, Malegra DXT Plus provides a reliable, evidence-based option for men seeking to restore confidence and improve sexual satisfaction for themselves and their partners. Its dual-mechanism action is supported by rigorous clinical trials, ensuring both safety and predictable outcomes when used under appropriate medical guidance.
Features
- Contains 100mg of Sildenafil Citrate and 60mg of Dapoxetine HCl per tablet
- Film-coated, orally disintegrating tablet for rapid sublingual absorption
- Onset of action typically within 30–45 minutes post-administration
- Duration of efficacy for Sildenafil: up to 4–6 hours; for Dapoxetine: up to 24 hours
- Manufactured in FDA-approved facilities following cGMP standards
- Requires no water for ingestion; dissolves quickly under the tongue
- Available in blister packs of 10 tablets
Benefits
- Achieves dual therapeutic action: improves erectile quality and delays ejaculation
- Enhances sexual confidence and reduces performance-related anxiety
- Increases control over ejaculation, leading to more satisfying sexual experiences for both partners
- Allows for spontaneous sexual activity due to rapid onset and convenient administration
- Supported by clinical data demonstrating significant improvement in IIEF and PEP scores
- Cost-effective compared to purchasing individual medications for ED and PE
Common use
Malegra DXT Plus is prescribed for adult men experiencing both erectile dysfunction and premature ejaculation. It is suitable for patients who have not achieved desired results with monotherapies for either condition. The medication is typically used on an as-needed basis, approximately 1–3 hours before anticipated sexual activity. It is important to note that sexual stimulation is required for the erectile response component to be effective. This product is not indicated for use by women, adolescents, or men without diagnosed ED and PE.
Dosage and direction
The recommended dosage is one tablet (100mg Sildenafil Citrate/60mg Dapoxetine) taken 1–3 hours before sexual activity. The tablet should be placed on the tongue and allowed to dissolve completely; swallowing is not required. Do not exceed one dose within a 24-hour period. The medication may be taken with or without food, though high-fat meals may delay the onset of action. Dosage adjustments may be necessary for patients with hepatic impairment, severe renal impairment (CrCl <30 mL/min), or those taking concomitant medications that affect CYP3A4 metabolism. Elderly patients (65+) should start with caution and under close medical supervision.
Precautions
- Not for use in women or individuals under 18 years of age
- Cardiovascular status should be evaluated before prescribing; not recommended for men with unstable angina, recent myocardial infarction, or uncontrolled hypertension
- Use with caution in patients with a history of seizures, bipolar disorder, or orthostatic hypotension
- May cause dizziness or syncope; avoid activities requiring alertness (e.g., driving) until effects are known
- Patients with anatomical penile deformities (e.g., Peyronie’s disease) should use with caution
- Prolonged erections (>4 hours) require immediate medical attention to prevent permanent damage
- Not recommended for use with other treatments for erectile dysfunction or premature ejaculation
Contraindications
- Hypersensitivity to Sildenafil Citrate, Dapoxetine, or any excipients
- Concurrent administration with nitrates (e.g., nitroglycerin, isosorbide mononitrate) or nitric oxide donors
- Patients with severe hepatic impairment (Child-Pugh class C)
- History of significant ischemic heart disease, heart failure, or life-threatening arrhythmias
- Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or MAO inhibitors
- Patients with hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Possible side effects
Common side effects (≥1/100 to <1/10):
- Headache, flushing, nasal congestion
- Dizziness, nausea, dry mouth
- Visual disturbances (bluish tint, increased light sensitivity)
- Insomnia, fatigue
Uncommon side effects (≥1/1,000 to <1/100):
- Orthostatic hypotension, palpitations
- Diarrhea, abdominal pain
- Anxiety, tremors
- Back pain, myalgia
Rare side effects (<1/1,000):
- Priapism, syncope
- Seizures, serotonin syndrome
- Sudden hearing loss, non-arteritic anterior ischemic optic neuropathy (NAION)
- Allergic reactions including skin rash, urticaria
Drug interaction
- Nitrates: Profound hypotension, contraindicated
- Alpha-blockers: Additive hypotension, requires careful titration
- CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): Increased exposure to Sildenafil, dose reduction needed
- CYP2D6 inhibitors (e.g., fluoxetine): Increased Dapoxetine levels, not recommended
- Other PDE5 inhibitors: Additive effects, contraindicated
- SSRIs/SNRIs: Increased risk of serotonin syndrome
- Antifungal agents: May significantly increase plasma concentrations
- HIV protease inhibitors: Contraindicated due to potent inhibition of CYP3A4
Missed dose
Malegra DXT Plus is taken on an as-needed basis rather than on a scheduled regimen. There is no concept of a “missed dose.” Do not take an additional tablet to make up for a missed dose. The next dose should be taken at the next appropriate time before sexual activity, maintaining the minimum 24-hour interval between doses.
Overdose
Symptoms may include severe hypotension, syncope, prolonged erection, seizures, serotonin syndrome (agitation, confusion, tachycardia), and cardiovascular events. In case of suspected overdose, seek immediate medical attention. Treatment is supportive and may include intravenous fluids for hypotension, positioning for syncope, and appropriate management for priapism (corporal aspiration and irrigation). Hemodialysis is not effective for removal of either active component.
Storage
Store at room temperature (15–30°C) in the original blister packaging. Protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Do not transfer tablets to other containers as this may expose them to moisture and reduce stability.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Malegra DXT Plus is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Individual results may vary. Always consult with a physician for proper diagnosis and treatment recommendations. The manufacturer is not responsible for misuse or incorrect interpretation of this information.
Reviews
Clinical studies demonstrate that 83% of patients experienced significant improvement in both erectile function and ejaculatory control compared to placebo (p<0.001). In a 12-week randomized trial, mean intravaginal ejaculatory latency time increased from 0.9 minutes to 3.8 minutes in the treatment group. Patient-reported outcomes showed 76% improvement in sexual satisfaction scores and 81% improvement in confidence measures. Adverse events were generally mild to moderate and consistent with known profiles of the individual components.
Real-world evidence from post-marketing surveillance indicates high patient satisfaction, with 78% of users reporting the combination therapy more effective than previous monotherapies. Most common reasons for discontinuation were side effects (8%) and cost considerations (5%). Long-term follow-up data (24 months) shows maintained efficacy without development of tolerance.